Hyperion SE (A7K)
XDUS XDUS Primary Summary
A7K Chart
Hyperion SE (A7K) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hyperion SE ever had a stock split?
Hyperion SE Profile
| Insurance Industry | Financials Sector | Dr. Michael Winlo CEO | XDUS Exchange | - ISIN |
| Australia Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Emyria Limited, located in Leederville, Australia, focuses on identifying and addressing unmet needs within mental health and specific neurological conditions. With its origins as Emerald Clinics Limited, the company underwent a rebranding in September 2020 to better reflect its expanded focus and was initially incorporated in 2018. By developing innovative treatments inspired by MDMA and other compounds, Emyria aims to offer new hope and improved therapies for individuals facing challenging health conditions. The company’s collaboration with the University of Western Australia underscores its commitment to groundbreaking research in the field of mental health and neurodegenerative diseases, including Parkinson's disease.
Products and Services
- EMD-MX1
An inspired version of MDMA, EMD-MX1 is designed to offer a faster-acting solution with a side-effect profile that is more manageable than traditional drug-assisted therapies. This addresses the critical need for effective, yet safer, mental health treatments.
- EMD-MX2
Targeting the neurological domain, particularly Parkinson's disease, EMD-MX2 serves as an adjunct therapy aimed at ameliorating the side effects associated with common Parkinson's treatments. This reflects Emyria’s commitment to improving quality of life for those battling this neurodegenerative condition.
- EMD-MX3
Geared towards addressing a broader range of neurological indications, EMD-MX3 embodies Emyria's dedication to expanding its impact within the neurological field through innovative drug development.
- EMD-RX7/9
At the forefront of Emyria’s cannabinoid-based medicine offerings, EMD-RX7/9 is a CBD capsule designed for prescription use. Currently in preclinical trials, this medicine targets complex pain and anxiety, indicating the company's venture into cannabinoid therapeutics alongside its psychedelic-inspired treatments.
- Pax Centre
In addition to drug development, Emyria operates the Pax Centre, a facility dedicated to the care of individuals suffering from psychological trauma. This illustrates the company’s holistic approach to mental health, focusing on both innovative medicines and supportive care services.
